Content in Context
The
next new thing (28 KB)
by James F. Ryan
News
in Brief (128 KB)
Patch over pill? Modeling medicine PSA the Raman way Promiscuous
pharma Split-pool mass spec Anthrax vaccine contract Surrogate
signs for SLE? Malarial prophylaxis problem
The Business Page (55 KB)
Marketplace,
deals, and people
The Executive Interview
Greg
Lucier, CEO, Invitrogen (57 KB)
Interviewed by James F. Ryan
and Felicia M. Willis
“I always wanted to mesh technology with business.”
For Your Health
Left
in knots (181 KB)
by Randall C. Willis
New treatments might keep inflammatory bowel disease from being a debilitating
disorder.
The Time Line
The
ghosts of pharma past (72 KB)
by Mark S. Lesney
Companies that were once household names can vanishhidden or dissolved in
mergers and acquisitions.
Applications NoteBook
Screening
for pharma gold (97 KB)
by John Lynch
Researchers are using membrane technologies for high-throughput ADME analysis. |
|
Sites and Software
Picture
perfect (82 KB)
by Janet L. Smith
To facilitate analysis, researchers are enlisting an image informatics solution
for high-content screening.
The Tool Box
Identifying
biowarfare agents (78 KB)
by Thomas Gluodenis and Craig Kunitsky
Automated analysis of fatty acid methyl esters helps prevent bioterrorism.
Rules and Regulators
The
FDA’s generic “Final Rule” (74 KB)
by Lee A. Goldberg and Nadine Farid
These HatchWaxman reforms seek balance.
Ready
to Read (93 KB)
- Designs for Life
Reviewed by Mark S. Lesney
- Burger’s Medicinal Chemistry
Reviewed by George B. Kauffman
On the Calendar
LabAutomation
2004 (68 KB)
The ALA’s annual show has a new California home.
The Word Puzzle
Genetic
miscellany (37 KB) | Solution
(html)
by Mark S. Lesney
Product
Info Now (html)
Diseases and Disorders
Mucopolysaccharidosis
I (56
KB)
by Randall C. Willis |